Prescribing information in 26 countries:: a comparative study

被引:24
作者
Reggi, V
Balocco-Mattavelli, R
Bonati, M [1 ]
Breton, I
Figueras, A
Jambert, E
Kopp, C
Montane, E
Rägo, L
Rocchi, F
机构
[1] Mario Negri Res Inst, Reg Drug Informat Ctr, Milan, Italy
[2] WHO, CH-1211 Geneva, Switzerland
[3] Int Soc Drug Bulletins, Paris, France
[4] Univ Autonoma Barcelona, Inst Catala Farmacol, E-08193 Barcelona, Spain
[5] Mario Negri Inst Pharmacol Res, Lab Mother & Child Hlth, I-20157 Milan, Italy
关键词
drug information; regulatory affairs; international survey;
D O I
10.1007/s00228-003-0607-1
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This study was set up to document the variability of prescribing information from different sources concerning indications, side effects and cautions of selected drugs. An original method to measure the degree of information agreement among different written materials, such as summaries of product characteristics, package inserts and data sheets, and a widely accepted reference text was developed. The results show that there is substantial disagreement in the materials available to prescribers and patients in different countries. Disagreement was even found within a single country when written materials from different brands of the same drug were compared. The discordance can be explained by the fact that the evidence available for each drug is considered/assessed differently by separate countries. It is argued that the discrepancies found may mislead prescribers, patients and those comparing drug-use patterns across countries. National regulatory authorities have a key role to play in remedying this situation, and a two-pronged approach is proposed. At the international level, national authorities should strengthen collaboration and information interchange and, at the national level, should implement appropriate measures aimed at removing contradictory statements on drug-information materials that have no reason to be different. Finally, further training and continued education aimed at drug regulatory officials could provide the necessary knowledge and enable national authorities to meet the need for drug information that is independent of commercial interests.
引用
收藏
页码:263 / 270
页数:8
相关论文
共 13 条
[1]  
American Society of Health System Pharmacist, 2001, AHFS DRUG INF
[2]  
[Anonymous], WORLD HLTH REP 2002
[3]   READABILITY OF PATIENT INFORMATION LEAFLETS ON OVER-THE-COUNTER (OTC) MEDICINES [J].
BRADLEY, B ;
SINGLETON, M ;
PO, ALW .
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 1994, 19 (01) :7-15
[4]  
Curran CF, 2000, DRUG INF J, V34, P1355, DOI 10.1177/009286150003400442
[5]   COMMERCIAL SOURCE OF DRUG INFORMATION - COMPARISON BETWEEN THE UNITED-KINGDOM AND INDIA [J].
DIKSHIT, RK ;
DIKSHIT, N .
BRITISH MEDICAL JOURNAL, 1994, 309 (6960) :990-991
[6]   How to improve medical information on drugs [J].
Garattini, S .
LANCET, 1998, 352 (9122) :151-152
[7]   THE BENEFITS OF PRESCRIPTION INFORMATION LEAFLETS .2. [J].
GIBBS, S ;
WATERS, WE ;
GEORGE, CF .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 28 (03) :345-351
[8]  
HOLT G A, 1992, American Pharmacy, V32, P58
[9]  
Mindell J, 1997, BRIT MED J, V315, P1622
[10]   Characteristics of materials distributed by drug companies - An evaluation of appropriateness [J].
Stryer, D ;
Bero, LA .
JOURNAL OF GENERAL INTERNAL MEDICINE, 1996, 11 (10) :575-583